Public Health Agency of Canada
Symbol of the Government of Canada

Share this page

Canadian Tuberculosis Standards 7th Edition

[Previous page] [Table of Contents] [Next page]

Chapter 2 - Pathogenesis and Transmission of Tuberculosis

Richard Long, MD, FRCPC, FCCP
Kevin Schwartzman, MD, MPH


Table of Contents

  1. Key Messages/Points
  2. Pathogenesis
  3. Transmission
  4. References

Key Messages/Points

  • Infection with Mycobacterium tuberculosis is acquired by inhalation of bacilli-containing droplet nuclei small enough (diameter 1-5 microns) to reach the alveoli.
  • Through innate immune mechanisms, alveolar macrophages eradicate the bacteria in some individuals; in others, the bacteria are able to replicate and establish tuberculosis (TB) infection. Bacterial factors and host genetic factors that promote or limit acquisition of infection are not well understood.
  • After infection with M. tuberculosis, early primary TB disease develops in 5% of people unless they first receive treatment for latent infection. Rapid progression to primary active TB is most frequent in infants and young children, and in people with immune compromise.
  • In another 5% of infected people there is later development of reactivation TB in the absence of treatment for latent TB infection (LTBI). Risks are much higher for people with immune compromise, notably HIV infection.
  • In the remaining 90% progression to active disease never occurs.
  • Intact cell-mediated immunity (CMI) is required to control and contain M. tuberculosis infection. Beyond evident clinical and radiographic risk factors, it is impossible to predict which infected people will ultimately develop active TB.
  • Transmission of M. tuberculosis occurs, with very few exceptions, via droplet nuclei, which can then be inhaled by those who are exposed. For this reason, only those with active pulmonary and/or laryngeal TB are likely to be contagious.
  • The probability of transmission increases with the following:
    • bacterial burden (smear positivity), cavitary and upper lung zone disease, and laryngeal disease;
    • amount and severity of cough in the source case;
    • duration of exposure;
    • proximity to the source case;
    • crowding and poorer room ventilation;
    • delays in diagnosis and/or effective treatment.
  • The most effective way to reduce transmission is to diagnose and treat patients with active TB disease as soon as possible.

Pathogenesis

The pathogenesis and transmission of TB are inter-related. M. tuberculosis is almost exclusively a human pathogen. How it interacts with the human host determines its survival. From the perspective of the bacterium a successful host-pathogen interaction is one that results in pathogen transmission. Initial infection is usually self-limited and followed by a variable period of latency, which ultimately, in a proportion of those infected, results in infectious pulmonary TB. Transmission from a case of infectious pulmonary TB is by the airborne route in minute droplets of moisture that become increasingly reduced by evaporation, creating "droplet nuclei"Footnote 1.

Evolution of Initial Infection and Host Response

At the time of initial infection, the distribution of inhaled droplet nuclei in the lung is determined by the pattern of regional ventilation. It thus tends to follow the most direct path to the periphery and to favour the middle and lower lung zones, which receive most of the ventilationFootnote 2. In immunocompetent hosts, it is theorized that alveolar macrophages ingest the M. tuberculosis organisms and may or may not destroy them, depending on the degree to which phagocytosing cells are nonspecifically activated, on host genetic factors and on resistance mechanisms in the bacteriaFootnote 3. If bacteria are successfully cleared, then test results will remain negative on the tuberculin skin test (TST) or interferon-gamma release assay (IGRA).

When innate macrophage microbicidal activity is inadequate to destroy the initial few bacteria of the droplet nucleus they replicate logarithmically, doubling every 24 hours until the macrophage bursts to release the bacterial progenyFootnote 3. New macrophages attracted to the site engulf these bacilli, and the cycle continues. The bacilli may spread from the initial lesion via the lymphatic and/or circulatory systems to other parts of the body. After a period lasting from 3 to 8 weeks the host develops specific immunity (cell-mediated immunity [CMI] and delayed-type hypersensitivity [DTH]) to the bacilli, and individuals typically show positive results on the TST or IGRA. The resulting M. tuberculosis-specific lymphocytes migrate to the site of infection, surrounding and activating the macrophages there. As the cellular infiltration continues, the centre of the cell mass, or granuloma, becomes caseous and necrotic. Radiographically demonstrable fibrocalcific residua of the initial infection include a Ghon focus (a calcified granuloma in the lung) alone or in combination with a calcified granulomatous focus in a draining lymph node (Ghon complex)Footnote 4 Footnote 5. Infection and immune conversion are usually asymptomatic; any symptoms that do occur are self-limited. In a small proportion of those infected, erythema nodosum (a cutaneous immunologic response to an extracutaneous TB infection) or phlyctenular conjunctivitis (a hypersensitivity reaction) may develop.

Early Disease Progression (Primary TB)

A proportion of those who are recently infected are unable to contain the infection despite the stimulation of CMI and DTH, and there is progression to disease in a matter of months. Such early disease progression is a function of age and immunologic response, disease being especially likely to occur in young children and the immunocompromised. A progressive Ghon focus, disseminated (miliary) disease and central nervous system disease may occur as early as 2 to 6 months after infection in infants and the severely immunocompromised Footnote 6 Footnote 7. Uncomplicated and asymptomatic lymph node disease (hilar or mediastinal lymphadenopathy without airway involvement) may also occur in the first 2-6 months of infection, although there is debate about whether this should be called active disease (refer to Chapter 9, Pediatric Tuberculosis) Footnote 6 Footnote 8.

At 4-12 months after infection, early disease manifestations include complicated lymph node disease (airway compression, expansile caseating pneumonia, infiltration of adjacent anatomic structures), pleural disease (most commonly a lymphocyte-predominant exudative effusion) and peripheral lymphadenitis (usually in the neck)Footnote 6. In immunocompetent children and adolescents early disease is more likely to manifest as intrathoracic adenopathy and in adults as a unilateral pleural effusion. In severely immunocompromised people of any age (e.g. those with advanced HIV or AIDS), early disease may manifest as intrathoracic adenopathyFootnote 9 Footnote 10. Rarely, in newly infected people who are 10 years of age or older (pubertal) adult-type pulmonary disease (refer to Figure 1) or other types of extrapulmonary TB (for example bone and joint TB) may develop within the first 24 months of infectionFootnote 11.

While early disease progression may or may not result from lympho-hematogenous spread, late disease progression (refer to Figure 1) is almost always the result of the lympho-hematogenous spread of bacilli. Recent infection with early disease progression probably accounts for many cases of TB in recently arrived immigrantsFootnote 12. For purposes of disease reporting, everyone with a diagnosis of TB made within 18-24 months of infection is considered to have "primary" disease (on balance about 5% of those infected). Those newly infected people in whom TB does not develop within this period of time will either be left with LTBI and will never experience disease (on balance about 90% of those infected) or, after a variable period of latency, they will develop late disease progression (on balance about 5% of those infected, refer to Figure 1).

Figure 1. The Pathogenesis of Tuberculosis in the Infected Host
(Adapted from the 6th Edition of the Canadian TB Standards)

Text Equivalent - Figure 1

Latent Tuberculosis Infection (LTBI)

In the classical concept of LTBI, M. tuberculosis bacteria are believed to survive for years in Ghon foci and complexes and in the small granulomas or solid caseous material of lympho-hematogenously seeded foci. Presumably, local conditions, an intact CMI or the presence of inhibitors result in conditions unfavourable to replication. Recent mapping of the complete genome sequence of the bacterium demonstrates that the organism has the potential to synthesize enzymes involved in anaerobic metabolismFootnote 13. Although rapid death and autolysis occur after abrupt depletion of oxygen, the organism can shift into a state of dormancy if allowed to settle through gradual reductions in oxygen tensionFootnote 14 Footnote 15. Therefore, although M. tuberculosis thrives in an aerobic environment, it possesses the genetic and biochemical capability of anaerobic survival and can persist experimentally in oxygen-depleted media. Tubercle formation, with its oxygen-depleted environment, is a defining characteristic of TB. LTBI is usually identified by a positive TST or IGRA in the absence of active disease (refer to Chapter 4, Diagnosis of Latent Tuberculosis Infection).

More recently LTBI and active TB have been considered as two ends of a spectrum of states ranging from asymptomatic infection to overt diseaseFootnote 16 Footnote 17. In this more nuanced concept, patients whose LTBI progresses to overt disease may pass through a continuum of asymptomatic intermediate states with detectable manifestations indicative of diseaseFootnote 16. Such asymptomatic disease states frequently remain undiagnosed, and their manifestations and duration are mostly dependent on host immune response. Defining these intermediate states in concrete terms is considered to be important for pragmatic reasons, as they might have an impact upon the performance of TB biomarkers or other diagnostic measures and could also present targets for therapeutic interventionsFootnote 16 Footnote 18.

Reinfection

The elegant studies of Ferguson strongly suggest that it takes up to 18 months after the initial infection for CMI to matureFootnote 19. During this period of time a reinfection carries the same risk of disease as the initial infection, perhaps explaining why disease is much more common in newly infected close contacts of smear-positive cases than it is in newly infected close contacts of smear-negative cases - the former having a greater likelihood than the latter of repeated exposure and reinfectionFootnote 20-22. Reinfection of immunocompetent hosts that occurs 18 months or more after the initial infection carries a much lower risk of progression to TB disease, estimated to be 21% of the risk of an initial infection progressing to diseaseFootnote 22. It is not known whether this is because prior infection without development of overt disease is simply a marker for people who are less susceptible to disease development or better able to overcome it once it has developed. Nevertheless, in highly endemic areas the majority of TB cases occurring in those with prior LTBI may be due to reinfection rather than reactivation; in Canada, where repeat exposure is much less common, most active TB reflects reactivation and not reinfectionFootnote 23-25. In the severely immunocompromised host, reinfection and initial infection carry a similarly high risk of disease regardless of when the reinfection occurred (refer to Chapter 6, Treatment of Latent Tuberculosis Infection).

Late Disease Progression (Reactivation TB)

In Canada, most TB is understood to be "reactivation" TB, i.e. occurring 18-24 months or more after the initial infection. It usually presents as adult-type pulmonary disease (upper lung zone fibrocavitary disease - previously referred to as postprimary TB - beginning in small foci that are the result of remote lympho-hematogenous spread), although it may also present as extrapulmonary TB. As mentioned earlier, adult-type pulmonary TB may on occasion be a manifestation of primary TB or a reinfection. In any population group, reactivation of LTBI, leading to reactivation TB, is much more likely to occur in people who are immunocompromised.

There are a number of theories, most of them speculative, as to why adult-type pulmonary TB tends to localize in the upper lung zones. These are described elsewhereFootnote 2 Footnote 5. People with a history of untreated or inadequately treated pulmonary TB or a "high-risk" lung scar (upper lung zone fibronodular abnormality) on chest radiograph are understood to have a higher bacillary burden than those without such a history/radiograph, and to be at increased risk of reactivation TBFootnote 26 Footnote 27.

From the standpoint of public health and the organism's survival as a species, adult-type pulmonary TB is the most important phenotypic expression of the disease. Patients with adult-type pulmonary TB are much more likely to show lung cavitation, created when caseous material liquefies (possibly related to hydrolytic enzymes released from inflammatory cells during their destruction and DTH to tuberculin-like proteins) and erodes into the bronchiFootnote 28. Within the unique extracellular environment of cavities, host defences are ineffectual, and bacteria multiply in large numbers. Because cavities are open to, and discharge their contents into, nearby bronchi these same bacteria are directly communicable to the outside air when the patient coughs. Transmission from patients with adult-type pulmonary TB is facilitated by the concurrent involvement of both the airways and their contiguous pulmonary blood supply at sites of disease in the lung. This minimizes the respiratory limitation experienced by the patient, extending the life of the host within the community and creating further opportunities for transmission before the patient either seeks medical attention or succumbsFootnote 29.

Extrapulmonary TB

Outside of the extrapulmonary sites of disease alluded to in the section Early Disease Progression and cases of bone and joint TB, whose timeline from infection to disease in children may be as short as a year, most extrapulmonary TB is reactivation disease. Extrapulmonary TB or combined pulmonary and extrapulmonary TB is more common in those who are severely immunocompromised; in those coinfected with HIV the occurrence of extrapulmonary TB increases as the CD4 count decreases (refer to Chapter 7, Non-respiratory Tuberculosis)Footnot9 Footnote 10.

Risk Factors for Progression from Infection to Disease

The risk of transition from LTBI to active TB, primary or reactivation, is largely dependent on the immune competency of the host. Age and sex appear to directly affect the immunologic response and the risk of disease: morbidity is greater among young children (<5 years of age), especially infants, among young adults, especially females, and among older adults, especially males. In high-burden countries, the population attributable fraction of undernutrition for TB is 27% according to the WHOFootnote 30. The seasonality of TB (with the highest incidence in spring and early summer) has been attributed to reduced sunlight and vitamin D deficiency during the winter months in some studies but not in othersFootnote 31-33. Ethnic differences have been offered as factors determining host immune response, with some supportFootnote 34, but differences among ethnic groups in all clinical forms of TB are probably best explained as phase differences in an epidemic waveFootnote 35. All races initially exposed in an epidemic as a group are equally susceptible, but eventually death and survival outcome select out people who are relatively more resistant. A growing body of evidence suggests that host genetic factors are important in determining susceptibility to TBFootnote 36-38. Most important from a clinical perspective are the many medical conditions that are well known to affect host immunologic response and increase the risk of progression from LTBI to active TB disease. These are reviewed in detail in Chapter 6, Treatment of Latent Tuberculosis Infection. To identify entry points for interventions aimed at addressing TB risk factors as well as social determinants, Lönnroth and colleagues developed a framework for proximate risk factors and upstream determinants of TB (refer to Figure 2)Footnote 39.

Figure 2. Framework for proximate risk factors and upstream determinants of TBFootnote 39

Text Equivalent - Figure 2


TransmissionFootnote 40-43

M. tuberculosis is communicable from one human to another mainly by the aerosol route and rarely through ingestion or percutaneous inoculation (e.g. through laboratory or hospital accident). Bovine TB, which in the past was caused by ingestion of milk heavily infected by M. bovis that then penetrated the mucosa of the oropharynx or the gastrointestinal tract, has been largely eradicated as a result of the pasteurization of milk and the tuberculin testing of cattle, followed by the slaughter of animals found to be infected.

The reservoir for M. tuberculosis is humans. Other animals, in particular primates, may be infected but are rarely a source of infectionFootnote 40-43. Droplet nuclei, sometimes referred to as "the quanta of contagion", are created by forceful expiratory efforts, such as coughing, sneezing, singing, playing wind instruments and even speaking. Before droplets reach the airspace of a room and have had an opportunity to evaporate down to a "droplet nucleus" their numbers can be reduced by wearing a simple gauze (surgical) mask or covering the mouth and nose during coughing. Certain procedures, for example, bronchoscopy, sputum induction, processing of specimens, autopsy and even irrigation or other manipulation of tuberculous abscesses, may also produce infectious aerosols. The droplets have an extremely slow settling rate (0.5 mm per second or less), which permits their transport by air currents, duct systems or elevator shafts for significant distances from the source case. Large particles settle quickly and are either not inhaled by contacts or, if inhaled, are trapped in the mucus of the upper airway. If the organism reaches the trachea and bronchi it is usually swept back to the larynx by ciliary action and cough, and then swallowed. For practical purposes, only the droplet nuclei in the size range 1 to 5 microns reach the terminal air spaces or alveoli; each is understood to contain only a few bacteria. In most instances only one such droplet nucleus is believed to be responsible for establishing infection in the host. Bacteria that are lodged on fomites (linen, furniture, books, floors) do not constitute a significant source of infection: most die quickly through the action of drying, heat or sunlightFootnote 5 Footnote 40-43.

The rate of transmission can be measured by the percentage of close contacts (household and non-household) whose TST or IGRA responses are converted from negative to positive or in whom active TB disease develops. The percentage will depend on the number of infectious droplet nuclei per volume of air (infectious particle density) and the length of time that the uninfected individual spends breathing that air. In the past, drug susceptibility patterns and phage typing of M. tuberculosis isolates have helped to confirm the transmission between source case and contact. More recently, DNA fingerprinting of M. tuberculosis isolates has greatly refined the identification of this relationFootnote 44.

Because of the highly variable latency period of M. tuberculosis infection it is difficult to precisely document transmission using currently available tools. People found to have positive TSTs and/or IGRAs during contact investigation may have been infected in the past (remotely) rather than by the recent source case of concern, though for contact management and public health purposes these contacts are treated as if recently infected if there is no way to determine the duration of infection. DNA fingerprinting techniques will only detect transmission to the small group of people in whom active disease develops following transmission. If most TB disease in a community reflects recent/ongoing transmission, the first priority for public health authorities should be to prevent further transmission. On the other hand, if most TB reflects reactivation of remotely acquired infection, the priority should shift to identification and treatment of people with LTBI, notably those with risk factors for reactivation.

Patient, Pathogen and Environmental Determinants of Transmission

Several patient, pathogen and environmental factors determine whether transmission occurs, largely by affecting the number of infectious droplet nuclei per volume of air (refer to Table 1). Although the probability of being infected after contact with an infectious source decreases with decreasing duration and decreasing closeness of contact, the absolute number of casual contacts infected may exceed the number of infected close contacts, since the former may far outnumber the latterFootnote 45. DNA fingerprint data have highlighted the limits of contact tracing in settings where there is exposure of a large number of people unknown to source cases and in settings where social connections are tenuous at bestFootnote 46 Footnote 47. At this point very little is known about what, if any, host determinants influence the acquisition of initial infection after inhalation of a droplet nucleus. Some individuals are able to achieve complete or "sterile" elimination of M. tuberculosis bacteria rather than developing latent infectionFootnote 48. Observational studies suggest that BCG vaccination in infancy offers some protection against infection with M. tuberculosis as detected by an IGRAFootnote 49-52.

Table 1. Patient, pathogen and environmental factors affecting transmission
Patient Pathogen Environment
Table 1 - Footnote A
CXR = chest radiograph
Disease type Strain variability Indoor/outdoor
Pulmonary
  • Smear-positive/smear-negative
  • Cavitary/non-cavitary on CXRTable 1 - Footnote A
  • Typical/atypical on CXR
  • Laryngeal
 
Air circulation/ventilation

Sunlight
Extrapulmonary   Proximity to the source case
Symptomatology   Duration of exposure
Delayed diagnosis    
Treatment    

Patient Factors

With rare exception (e.g. transmission related to an inadequately sterilized bronchoscope or a needle stick injury), transmission requires that a TB patient be able to produce airborne infectious dropletsFootnote 41-43. This most often limits the potential for transmission to adolescent or adult patients with adult-type pulmonary TB. Younger children can on occasion be infectiousFootnote 53, but as a general rule they have few bacilli in their lesions, often do not produce sputum and rarely have communicable diseaseFootnote 54. Of patients with TB involving the respiratory tract not all are equally efficient at transmission.

1. Sputum smear status
Patients with smear-positive/culture-positive pulmonary TB are more infectious than patients with smear-negative/culture-positive pulmonary TB, and the latter are more infectious than patients with smear-negative/culture-negative pulmonary TB (refer to Table 2 for a summary of the epidemiologic studies on the risk of infection in household [close] contacts grouped according to the bacteriologic status of the source cases)Footnote55-62. Sputum that is smear-positive contains 5,000 or more organisms per millilitre of sputumFootnote 57 Footnote 58 Footnote 63 Footnote 64 Patients with smear-positive bronchoalveolar lavage fluid are considered just as infectious as those with smear-positive sputumFootnote 65. Smear-positive induced sputum is for practical purposes considered to indicate the same degree of contagiousness as smear-positive spontaneously expectorated sputum, though there are currently no data that prove this assertionFootnote 55. With the use of molecular epidemiologic tools the relative transmission rate of smear-negative compared with smear-positive patients has been determined to be 0.17-0.22 or roughly one-fifth the likelihood of transmissionFootnote 66 Footnote 67. In addition to the greater infectivity of smear-positive cases, as mentioned in the section Pathogenesis, the risk of disease after infection from a smear-positive case is greater, by virtue of the higher probability of repeated infection, than it is after infection from a smear-negative case.

Table 2. Footnote A Risk of infection among household (close) contacts according to bacteriologic status of index case (pulmonary TB only)
Ref no. Year of survey Location Contacts Number and % infected contacts by bacteriologic status of index case General population % positive PPDBTable 2 - Footnote B
S+C+ S+C+ S+C+
Age Total no. N %+ N %+ N %+
Table 2 - Footnote A
Adapted from reference number 55
Table 2 - Footnote B
Taken from the same reference, i.e. a comparable reference population.
Table 2 - Footnote C
In this study contacts were considered infected only if tuberculin conversion and/or primary TB had been documented.
Table 2 - Footnote
S = smear, C = culture, PPD = purified protein derivative
56 1949-56 England 0-14 545 262 63% 126 21% 157 18% 13%
57 1950-53 England 0-14 823 374 65% 228 27% 221 18% 22%
58 1963-64 Holland all ages 858Footnote C 391 20% 467 1% - - << 1%
20 1966-71 Canada-Whites 0-19 2406 1210 38% 655 12% 541 10% 2%
NA NA Canada Aboriginals 0-19 1168 592 45% 377 31% 199 27% NA
59 1967-69 Rotterdam 0-14 134 40 50% 43 5% 51 8% 1%
60 1969 USA all ages 130 88 44% 14 21% 28 14% NA
61 1971-74 USA all ages 761 504 46% 257 28% - - NA
62 1975-77 USA all ages 541 368 40% 173 27% - - NA

2. Disease type on plain chest radiograph
Pulmonary TB patients with cavitation on chest radiograph are more infectious than pulmonary TB patients without cavitation after bacteriologic findings have been taken into account Footnote 68-70. Pulmonary TB patients with "typical" chest radiographic findings (upper lung zone disease, with or without cavitation, and no discernable intrathoracic adenopathy) are more infectious than pulmonary TB patients with "atypical" chest radiographic findings (all others)Footnote 71.

3. Laryngeal disease
Patients with laryngeal TB are more infectious than those with pulmonary TBFootnote 72. Most patients with laryngeal TB (hoarseness associated with inflammation and ulceration of the vocal cords) have far advanced pulmonary disease upstream from the larynxFootnote 73.

4. Symptomatology
In general, normal breathing produces few infectious particles, a bout of coughing or five minutes of speaking in a normal tone produce many more, and a sneeze produces the mostFootnote 74 Footnote 75. The likelihood that household contacts will be infected increases with the frequency of cough in the source caseFootnote 60. When the aerial infectivity of the droplets from smear-positive patients was evaluated by artificially atomizing sputum and exposing guinea pigs to a standard dose, there was marked variability in the infectivity of aerosolized sputum, perhaps explaining the extraordinary heterogeneity of infectiousness among patients with smear-positive pulmonary TBFootnote 76-78. Thus, although patients may appear to have an equal number of bacteria in their sputum, the physical and chemical properties of their sputum, as well as their effectiveness as an aerosolizer, may determine whether they produce a large or small number of droplet nuclei. The role of smoking, allergy or coincidental viral upper respiratory tract infection in aerosol formation is unknownFootnote 79.

5. Delayed diagnosis
The number of contacts and the duration of exposure of each contact may increase as time to diagnosis increases. The longer the duration of symptoms in the source case the greater the risk of transmissionFootnote 65.

6. Treatment
Effective treatment (refer to Chapter 5, Treatment of Tuberculosis Disease) appropriate to the drug susceptibility test results rapidly reduces cough frequency and sputum bacillary countsFootnot60 Footnote 80. Even faster than the rate of decrease of the latter is the rate of decrease of bacillary counts in cough-generated aerosol culturesFootnote 81. With treatment those bacteria that continue to be expectorated may be expected to be less metabolically active and/or are inhibited by the drugs, two effects that may decrease the chances of the organism establishing an infection in the hostFootnote 76 Footnote 82. However, in theory, any residual viable bacteria in respiratory secretions can be transmitted, although the chances of this occurring decrease rapidly with effective treatmentFootnote 83. Given the frequency of drug resistance, the determination that treatment is effective in reducing the infectiousness of a given patient should reflect objective clinical, radiographic and/or microbiologic improvement, and not simply time elapsed since treatment initiation.

Pathogen Factors

Data are emerging to suggest that one or more virulence properties of M. tuberculosis may affect its ability to be transmittedFootnote 84. For example, one strain may be better suited than another to overcoming the innate resistance of the host. Although drug-resistant strains have shown reduced virulence in animal modelsFootnote 85, clinical evidence of their transmissibility is compellingFootnote 86-89, and for practical purposes they should be considered just as transmissible as drug-susceptible strains. Beijing/W strains have been reported to be hypervirulent, but indices of transmission have been found to be no greater in patients with these strains than in those without themFootnote 90.

Environmental Factors

Outdoor exposures are very unlikely to result in transmission unless the source and the susceptible person are in talking distance. Bacillary dispersion is immediate, and sunlight rapidly kills any viable bacilliFootnote 91 Footnote 92. For practical purposes outdoor exposures are not investigated during a contact tracing exercise.

1. Air circulation and ventilation
Given a defined number of bacteria expelled into the air, the volume of air into which the bacteria are expelled determines the probability that a susceptible individual breathing that air will become infected. A high concentration of viable bacteria in the inhaled air of the contact is favoured by indoor exposure, poor ventilation or recirculation of air, and little sunlight (ultraviolet rays). Ventilation dramatically dilutes the concentration of infectious droplet nuclei (refer to Chapter 15, The Prevention and Control of Tuberculosis Transmission in Health Care and Other Settings, for further information on clearance times).

2. Proximity to the source case
Proximity to the source case is also a determinant of transmission. Related to this is overcrowding: if, as a result of there being many people in a room, an individual is forced into close proximity with an infectious case his or her risk of infection is likely to increase.

3. Duration of exposure
Because of the dilution of infected air and the low concentration of infectious droplet nuclei, the duration of exposure required to ensure that transmission occurs is commonly prolonged (days, months or even years), and yet reports have confirmed that exposures as short as a few minutes may be sufficient to infect a close contact. The latter would appear to be supported by the high proportion of active cases that deny any history of exposure.

Measures to Prevent Transmission

The highest priority should be given to early diagnosis and prompt, effective treatment of the source case together with isolation of the patient when necessary. The insidious development of symptoms in most cases of TB commonly results in a delay of weeks or months before the patient presents for diagnosis. At that point, when the patient is often at his or her most infectious, any further delay caused by the physician, nurse or system allows unnecessary transmission to others. Maintaining an appropriate awareness of TB among health care providers is thus critical to reducing transmission and initiating early prevention and treatment. Administrative and engineering controls that aim to reduce exposure in health care and other congregate settings complement--but cannot replace--prompt diagnosis and appropriate therapy. Methods once thought to be important in preventing the transmission of TB - disposing of such personal items as cloths or bedding, sterilizing fomites, using caps and gowns, gauze or paper masks, boiling dishes and washing walls - are unnecessary, because they have no bearing on airborne transmission.


References

Footnote 1
Wells WF. Airborne Contagion and Air Hygiene. Cambridge, MA: Harvard University Press, 1995. http://onlinelibrary.wiley.com/doi/10.1111/j.1746-1561.1955.tb08015.x/abstract
Footnote 2
Murray JF. Bill Dock and the location of pulmonary tuberculosis: how bed rest might have helped consumption. Am J Respir Crit Care Med 2003;168:1029-33. http://www.atsjournals.org/doi/pdf/10.1164/rccm.200307-1016OE
Footnote 3
Woolwine SC, Bishai WR. Overview of the pathogenesis of tuberculosis from a cellular and molecular perspective. In: Raviglione MC, ed. Reichman and Hershfield&rsquo;s Tuberculosis, A Comprehensive International Approach, 3rd Edition. New York: Informa Healthcare, 2006;101-16.
Footnote 4
Ghon A. The Primary Lung Focus of Tuberculosis in Children. London, UK: Churchill, 1916.
Footnote 5
Allen EA. Tuberculosis and other mycobacterial infections of the lung. In: Thurlbeck WM, Churg AM, eds. Pathology of the Lung (2nd edition). New York: Thieme Medical Publishers Inc., 1995;229-302.
Footnote 6
Perez-Valez CM, Marais BJ. Current concepts: tuberculosis in children. N Engl J Med 2012;367(4):348-61. http://www.nejm.org/doi/full/10.1056/NEJMra1008049
Footnote 7
Daley CD, Small PM, Schecter GS, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992;326:231-35. http://www.nejm.org/doi/full/10.1056/NEJM199201233260404
Footnote 8
Marais BJ, Gie RP, Schaaf HS, et al. The natural history of childhood intrathoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis 2004;8:392-402. http://www.ncbi.nlm.nih.gov/pubmed/15141729
Footnote 9
Post FA, Wood R, Pillay GP. Pulmonary tuberculosis in HIV infection: radiographic appearance is related to CD4+ T lymphocyte count. Tubercle Lung Dis 1995;76:518-21. http://www.sciencedirect.com/science/article/pii/0962847995905278
Footnote 10
Burman WJ, Jones BE. Clinical and radiographic features of HIV-related tuberculosis. Semin Respir Infect 2003;18:263-71.http://www.ncbi.nlm.nih.gov/pubmed/14679475
Footnote 11
Stead WW, Kerby GR, Schleuter DP, Jordahl CW. The clinical spectrum of primary tuberculosis in adults. Confusion with reinfection in the pathogenesis of chronic tuberculosis. Ann Intern Med 1968;68:731-44. http://annals.org/article.aspx?articleid=682153
Footnote 12
Langlois-klassen D, Wooldrage KM, Manfreda J, et al. Piecing the puzzle together: foreign-born tuberculosis in an immigrant receiving country. Eur Respir J 2011;38:895-902.http://erj.ersjournals.com/content/38/4/895.full.pdf
Footnote 13
Wilson RJ, Pillay DG, Sturm AW. Mycobacterium tuberculosis is not an obligate aerobe. J Infection 1999;38:197-8. http://www.ncbi.nlm.nih.gov/pubmed/10424804
Footnote 14
Wayne LG, Diaz GA. Autolysis and secondary growth of Mycobacterium tuberculosis in submerged culture. J Bacteriol 1967;93:1374-81. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC276611/pdf/jbacter00410-0208.pdf
Footnote 15
Wayne LG, Lin KY. Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions. Infect Immun 1982;37:1042-49. http://iai.asm.org/content/37/3/1042
Footnote 16
Achkar JM, Jenny-Avital ER. Incipient and subclinical tuberculosis: defining early disease in the context of immune response. J Infect Dis 2011;204:S1179-86. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3192549/pdf/jir451.pdf
Footnote 17
Lawn SD, Wood R, Wilkinson RJ. Changing concepts of &ldquo;latent tuberculosis infection&rdquo; in patients living with HIV infection. Clin Devop Immunol 2011;doi:10.1155/2011/980594. http://www.hindawi.com/journals/jir/2011/980594/
Footnote 18
Robertson BD, Altmann D, Barry C, et al. Detection and treatment of subclinical tuberculosis. Tuberculosis 2012;92:447-52. http://www.ncbi.nlm.nih.gov/pubmed/22819716
Footnote 19
Ferguson RG. Studies in Tuberculosis. Toronto: University of Toronto Press, Canada, 1955.
Footnote 20
Gryzbowski S, Barnett GD, Styblo K. Contacts of cases of active pulmonary tuberculosis. Report #3 of TSRU. Bull Int Union Tuberc 1975;50:90-106. http://www.ncbi.nlm.nih.gov/pubmed/1218291
Footnote 21
Houk V, Kent D, Baker J, et al. The Byrd Study. Arch Environ Health 1968;16:4-6. http://www.ncbi.nlm.nih.gov/pubmed/5635589
Footnote 22
Houk V, Baker J, Swensen K, Kent D. The epidemiology of tuberculosis in a closed environment. Arch Environ Health 1968;16:26-35. http://www.ncbi.nlm.nih.gov/pubmed/5638222
Footnote 23
Andres JR, Farzad N, Wolensky RP, Cerda R, Losina E, Horsburgh CR. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis 2012;54:784-91. http://cid.oxfordjournals.org/content/54/6/784.full.pdf
Footnote 24
Vynnycky E, Fine PE. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect 1997;119:183-201. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808840/pdf/9363017.pdf
Footnote 25
Cohen T, Murray M. Incident tuberculosis among recent US immigrants and exogenous reinfection. Emerg Infect Dis 2005;11;725-8. http://wwwnc.cdc.gov/eid/article/11/5/pdfs/04-1107.pdf
Footnote 26
Krivinka R, Drapela J, Kubik A, et al. Epidemiological and clinical study of tuberculosis in the district of Kolin, Czechoslovakia. Second report (1965-1972). Bull World Health Organ 1974;51:59-69. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2554234/pdf/bullwho00245-0003.pdf
Footnote 27
Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 1982;60:555-64. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2536088/pdf/bullwho00106-0107.pdf
Footnote 28
Dannenburg AM, Sugimoto M. Liquefaction of caseous foci in tuberculosis. Am Rev Respir Dis 1976;113:257-9. http://www.ncbi.nlm.nih.gov/pubmed/816235
Footnote 29
Long R, Maycher B, Dhar A, Manfreda J, Hershfield E, Anthonisen N. Pulmonary tuberculosis treated with directly observed therapy: serial changes in lung structure and function. Chest 1998;113:933-43. http://journal.publications.chestnet.org/data/Journals/CHEST/21763/933.pdf
Footnote 30
L&ouml;nnroth K, Castro K, Chakaya JM, et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet 2010;375(9728):1814-29. DOI: 10.106/S0140-6736(10)60483-7. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60483-7/abstract
Footnote 31
Martineau AR, Nhamoyebonde S, Oni T, et al. Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. Proc Natl Acad Sci U S 2011;108:19013-17. http://www.pnas.org/content/early/2011/10/18/1111825108.full.pdf
Footnote 32
Fares A. Seasonality of tuberculosis. J Glob Infect Dis 2011;3:46-55. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068579/
Footnote 33
Willis MD, Winston CA, Heilig CM, Cain KP, Nicholas DW, Mac Kenzie WR. Seasonality of tuberculosis in the United States 1993-2008. Clin Infect Dis 2012;54:1553-60. http://cid.oxfordjournals.org/content/54/11/1553.full.pdf
Footnote 34
Stead WW, Lofgren JP, Senner JW, Reddick WT. Racial differences in susceptibility to infection with M. tuberculosis. N Engl J Med 1990;322:422-27. http://www.nejm.org/doi/pdf/10.1056/NEJM199002153220702
Footnote 35
Grigg ERN. Arcana of tuberculosis. Am Rev Respir Dis 1958;78:151-72. http://www.ncbi.nlm.nih.gov/pubmed/13571601
Footnote 36
Greenwood C, Fujiwara T, Boothroid L, et al. Linkage of tuberculosis to chromosome 2q35 loci, including NRAMP 1, in a large Aboriginal family. Am J Hum Genet 2000;67:405-16. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1287187/pdf/AJHGv67p405.pdf
Footnote 37
Bellamy R. Susceptibility to mycobacterial infections: the importance of host genetics. Genes Immun 2003;4:4-11. http://www.nature.com/gene/journal/v4/n1/pdf/6363915a.pdf
Footnote 38
Pan H, Yan B-S, Rojas M, et al. IPR1 gene mediates innate immunity to tuberculosis. Nature 2005;434:767-72. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1388092/pdf/nihms3836.pdf
Footnote 39
Lönnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med 2009;68(12):2240-06. DOI:10.1016/j.socscimed.2009.03.041. http://www.ncbi.nlm.nih.gov/pubmed/19394122
Footnote 40
Mycobacteria. In: Fraser RS, Müller NL, Colman N, Paré PD, eds. Diagnosis of Diseases of the Chest (4th edition). Toronto: W.B. Saunders Company, 1999;798-873. http://pubs.rsna.org/doi/pdf/10.1148/radiology.217.1.r00se51262
Footnote 41
Adler JJ, Rose DN. Transmission and pathogenesis of tuberculosis. In: Rom WN, Garey S, eds. Tuberculosis. Toronto: Little, Brown and Company, 1996:129-40.
Footnote 42
Bates JH. Transmission, pathogenesis, pathology and clinical manifestations of tuberculosis. In: Kubica GP, Wayne LG, eds. The Mycobacteria: A Sourcebook. Part B (Microbiology Series, Vol. 15). New York: Marcel Dekker, Inc., 1984;991-1005.
Footnote 43
How is tuberculosis transmitted? In: Iseman MD, ed. A Clinician's Guide to Tuberculosis. New York: Lippincott Williams and Wilkins, 2000;51-62.
Footnote 44
Barnes P, Cave D. Molecular epidemiology of tuberculosis. N Engl J Med 2003;349:1149-56. http://www.nejm.org/doi/full/10.1056/NEJMra021964
Footnote 45
Rieder H. Infection with tubercle bacilli. In: Rieder H, ed. Epidemiologic Basis of Tuberculosis Control. Paris: International Union Against Tuberculosis and Lung Disease, 1999;17-63. http://www.theunion.org/what-we-do/publications/english/pub_epidemiologic_basis_eng.pdf
Footnote 46
Barnes PF, Yang Z, Preston-Martin S, et al. Patterns of tuberculosis transmission in central Los Angeles. JAMA 1997:278:1159-63. http://jama.jamanetwork.com/article.aspx?articleid=418341
Footnote 47
von Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999;341:1174-79. http://www.nejm.org/doi/full/10.1056/NEJM199910143411602
Footnote 48
Ottenhoff THM. The knowns and unknowns of the immunopathogenesis of tuberculosis. Int J Tuberc Lung Dis 2012;16:1424-32. http://www.ncbi.nlm.nih.gov/pubmed/23044443
Footnote 49
Soysal A, Millington KA, Bakir M, et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 2005;366:1443-51. http://www.sciencedirect.com/science/article/pii/S0140673605675344
Footnote 50
Eisenhut M, Paranjothy S, Abubakar I, et al. BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay. Vaccine 2009;27:6116-20. http://www.sciencedirect.com/science/article/pii/S0264410X09012079
Footnote 51
Eriksen J, Chow JH, Mellis V, et al. Protective effect of BCG vaccination in a nursery outbreak in 2009: time to reconsider the vaccination threshold? Thorax 2010;65:1067-71. http://thorax.bmj.com/content/65/12/1067.full.pdf
Footnote 52
Roy RB, Sotgiu G, Altet-G&oacute;mez N, et al. Identifying predictors of interferon-&gamma; release assay results in pediatric latent tuberculosis: a protective role of bacillus Calmette-Gu&eacute;rin? A pTB-NET collaborative study. Am J Respir Crit Care Med 2012;186:378-84. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3443812/pdf/AJRCCM1864378.pdf
Footnote 53
Curtis AB, Ridzon R, Vogel R, McDonough S, et al. Extensive transmission of Mycobacterium tuberculosis from a child. N Engl J Med 1999;341(20):1491-95. http://www.nejm.org/doi/full/10.1056/NEJM199911113412002
Footnote 54
Starke JR. Transmission of tuberculosis to and from children and adolescents. Semin Pediatr Infect Dis 2001;12:115-23. http://www.sciencedirect.com/science/article/pii/S1045187001700271
Footnote 55
Menzies D. Issues in the management of contacts of patients with active pulmonary tuberculosis. Can J Public Health 1997;88:197-201. http://www.ncbi.nlm.nih.gov/pubmed/9260361
Footnote 56
Van Zwanenberg D. The influence of the number of bacilli on the development of tuberculosis disease in children. Am Rev Respir Dis 1960;82:31-44. http://www.ncbi.nlm.nih.gov/pubmed/13841166
Footnote 57
Shaw JB, Wynn-Williams N. Infectivity of pulmonary tuberculosis in relation to sputum status. Am Rev Tuberc 1954;69:724-32. http://www.ncbi.nlm.nih.gov/pubmed/13148535
Footnote 58
Rouillon A, Perdrizet S, Parrot R. Transmission of tubercle bacilli: the effects of chemotherapy. Tubercle 1976;57:275-99. http://www.ncbi.nlm.nih.gov/pubmed/827837
Footnote 59
Van Geuns HA, Meijer J, Styblo K. Results of contact examination of Rotterdam, 1967-1969. Bull Int Union Tuberc 1975;50:107-21. http://www.ncbi.nlm.nih.gov/pubmed/1218286
Footnote 60
Loudon RG, Romans WE. Cough frequency and infectivity in patients with pulmonary tuberculosis. Am Rev Respir Dis 1969;99:109-11. http://www.ncbi.nlm.nih.gov/pubmed/5762102
Footnote 61
Rose CE, Zerbe GO, Lantz SO, Bailey WC. Establishing priority during investigation of tuberculosis contacts. Am Rev Tuberc 1979;119:603-09. http://www.ncbi.nlm.nih.gov/pubmed/443630
Footnote 62
Snider DE, Kelly GD, Cauthen GM, Thompson NJ, Kilburn JO. Infection and disease among contacts of tuberculosis cases with drug-resistant and drug susceptible bacilli. Am Rev Resp Dis 1985;132:125-32. http://www.ncbi.nlm.nih.gov/pubmed/3925826
Footnote 63
Yeager H Jr, Lacy J, Smith LR, et al. Quantitative studies of mycobacterial populations in sputum and saliva. Am Rev Respir Dis 1967;95:998-1004. http://www.ncbi.nlm.nih.gov/pubmed/4961042
Footnote 64
Gryzbowski S, Allen E. The challenge of tuberculosis in decline. Am Rev Respir Dis 1964;90:707-20. http://www.ncbi.nlm.nih.gov/pubmed/14211457
Footnote 65
Lohmann EM, Koster BFPJ, le Cassie S, et al. Grading of positive sputum smear and the risk of Mycobacterium tuberculosis transmission. Int J Tuberc Lung Dis 2012;16(11):1477-84. http://www.ncbi.nlm.nih.gov/pubmed/22964038
Footnote 66
Behr MA, Warren SA, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 1999;353:444-49. http://www.sciencedirect.com/science/article/pii/S0140673698034060
Footnote 67
Hernandez-Garduno E, Cook V, Kunimoto D, et al. Transmission of tuberculosis from smear negative patients: a molecular epidemiology study. Thorax 2004;59:286-90. http://thorax.bmj.com/content/59/4/286.full.pdf
Footnote 68
Catanzaro A. Nosocomial tuberculosis. Am Rev Respir Dis 1982;125:559-62. http://www.ncbi.nlm.nih.gov/pubmed/7081816
Footnote 69
Bailey WC, Gerald LB, Kimerling ME, et al. Predictive model to identify positive tuberculosis skin test results during contact investigations. JAMA 2002;287:996-1002. http://jama.jamanetwork.com/article.aspx?articleid=194678
Footnote 70
Marks SM, Taylor Z, Qualls NL, et al. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med 200;162:2033-8. http://www.atsjournals.org/doi/pdf/10.1164/ajrccm.162.6.2004022
Footnote 71
Lau A, Barrie J, Winter C, et al. The public health consequences of smear-positive pulmonary tuberculosis in patients with typical versus atypical chest radiographs. International Union against Tuberculosis and Lung Disease North American Regional Meeting. February 24-26, 2011, Vancouver, BC.
Footnote 72
Muecke C, Isler M, Menzies D, et al. The use of environmental factors as adjuncts to traditional tuberculosis contact investigation. Int J Tuberc Lung Dis 2006;10:530-35. http://www.ncbi.nlm.nih.gov/pubmed/16704035
Footnote 73
Rieder HL. The infectiousness of laryngeal tuberculosis: appropriate public heath action based on false premises. Int J Tuberc Lung Dis 2009;13:4-5. http://www.ncbi.nlm.nih.gov/pubmed/19105872
Footnote 74
Louden RG, Roberts RM. Droplet expulsion from the respiratory tract. Am Rev Respir Dis 1967;95:435-42. http://www.ncbi.nlm.nih.gov/pubmed/6018703
Footnote 75
Louden RG, Roberts RM. Singing and the dissemination of tuberculosis. Am Rev Respir Dis 1968;98:297-300. http://www.ncbi.nlm.nih.gov/pubmed/5667756
Footnote 76
Riley RL, Mills CC, Nyka W, et al. Aerial dissemination of pulmonary tuberculosis: a two year study of contagion in a tuberculosis ward. Am J Hyg 1959;70:185-96. http://aje.oxfordjournals.org/content/142/1/3.long
Footnote 77
Sultan L, Nyka W, Mills C, et al. Tuberculosis disseminators: a study of the variability of aerial infectivity of tuberculosis patients. Am Rev Respir Dis 1960;82:358-69. http://www.ncbi.nlm.nih.gov/pubmed/13835667
Footnote 78
Riley RL, Mills CC, O&rsquo;Grady F, et al. Infectiousness of air from a tuberculosis ward&mdash;ultraviolet irradiation of infected air: comparative infectiousness of different patients. Am Rev Respir Dis 1962;85:511-25. http://www.ncbi.nlm.nih.gov/pubmed/14492300
Footnote 79
Stein RA. Super-spreaders in infectious diseases. Int J Infect Dis 2011;15:e510-e513. http://www.sciencedirect.com/science/article/pii/S1201971211000245
Footnote 80
Jindani A, Aber VR, Edwards EA, et al. The early bacteriocidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980;121:939-49. http://www.ncbi.nlm.nih.gov/pubmed/6774638
Footnote 81
Fennelly KP, Martyny JW, Fulton KA, et al. Cough generated aerosols of Mycobacterium tuberculosis. Am J Respir Crit Care Med 2004;169;604-09. http://www.atsjournals.org/doi/pdf/10.1164/rccm.200308-1101OC
Footnote 82
Long R, Bochar K, Chomyc S, et al. Relative versus absolute noncontagiousness of respiratory tuberculosis on treatment. Infect Control Hosp Epidemiol 2003;24:831-38. http://www.jstor.org/stable/10.1086/502145
Footnote 83
Hopewell PC. Factors influencing the transmission and infectivity of Mycobacterium tuberculosis: implications for clinical and public health management. In: Sande MA, Hudson LD, Root RK, eds. Respiratory Infections. New York: Churchill Livingstone, 1986;191-216.
Footnote 84
Albanna AS, Reed MB, Kotar KV, et al. Reduced transmissibility of East African Indian Strains of Mycobacterium tuberculosis. PLOS One 2011; 6:e25075.doi:10.1371/journal.pone.0025075. http://www.plosone.org/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0025075&representation=PDF
Footnote 85
Middlebrook G, Cohn ML. Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli. Science 1953;118 (3063):297-99. http://www.ncbi.nlm.nih.gov/pubmed/13089681
Footnote 86
Schaaf HS, Marais BJ, Hesseling AC, et al. Childhood drug-resistant tuberculosis in the Western Cape Province of South Africa. Acta Paediatr 2006;95:523-8. http://www.ncbi.nlm.nih.gov/pubmed/16825130
Footnote 87
Moss AR, Alland D, Telzak E, et al. A city wide outbreak of a multiple-drug-resistant strain of Mycobacterium tuberculosis in New York. Int J Tuberc Lung Dis 1997;1:115-21. http://www.ncbi.nlm.nih.gov/pubmed/9441074
Footnote 88
Drobniewski F, Balabanova Y, Nikolayevsky V, et al. Drug-resistant tuberculosis, clinical virulence, and the dominance of the Beijing strain family in Russia. JAMA 2005;293:2726-31. http://jama.jamanetwork.com/article.aspx?articleid=201037
Footnote 89
Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368:1575-80. http://www.sciencedirect.com/science/article/pii/S0140673606695731
Footnote 90
Langlois-Klassen D, Senthilselvan A, Chui L, et al. Transmission of Mycobacterium tuberculosis Beijing strains, Alberta, Canada, 1991-2007. Emerg Infect Dis (in press). http://wwwnc.cdc.gov/eid/article/19/5/12-1578_intro.htm
Footnote 91
Edwards LB, Tolderlund K. BCG vaccine studies. 3. Preliminary report on the effect of sunlight on BCG vaccine. Bull World Health Organ 1952;5:245-48. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2554094/pdf/bullwho00635-0119.pdf
Footnote 92
Edwards LB, Dragsted I. BCG vaccine studies. 4. Further observations on the effect of light on BCG vaccine. Bull World Health Organ 1952;5:333-36. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2554035/pdf/bullwho00636-0076.pdf

[Previous page] [Table of Contents] [Next page]